Reports and Our Data of MDR1/P-gp Expression and Clinical Course of AML Patients
| Investigators . | Year and References . | Methods . | Samples . | CR Rate (%) . | |
|---|---|---|---|---|---|
| MDR1/P-gp Positive . | MDR1/P-gp Negative . | ||||
| Kuwazuru et al | 1990 (14) | Western blot | 19 | 1/10 (10%) | 7/9 (77%) |
| Marie et al | 1991 (15) | Northern blot | 29 | 7/21 (30%) | 5/8 (63%) |
| Campos et al | 1992 (16) | FACS | 150 | 23/71 (32%) | 64/79 (81%) |
| Nüssler et al | 1996 (17) | FACS | 166 | 26/88 (29%) | 93/141 (66%) |
| Nakayama et al | This study | Quantitative RT-PCR | 34 | 7/21 (33%) | 8/13 (62%) |
| Investigators . | Year and References . | Methods . | Samples . | CR Rate (%) . | |
|---|---|---|---|---|---|
| MDR1/P-gp Positive . | MDR1/P-gp Negative . | ||||
| Kuwazuru et al | 1990 (14) | Western blot | 19 | 1/10 (10%) | 7/9 (77%) |
| Marie et al | 1991 (15) | Northern blot | 29 | 7/21 (30%) | 5/8 (63%) |
| Campos et al | 1992 (16) | FACS | 150 | 23/71 (32%) | 64/79 (81%) |
| Nüssler et al | 1996 (17) | FACS | 166 | 26/88 (29%) | 93/141 (66%) |
| Nakayama et al | This study | Quantitative RT-PCR | 34 | 7/21 (33%) | 8/13 (62%) |